EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prostate‐Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer

Niranjan Meher iD, Gary W Ashley, Kondapa Naidu Bobba, Anju Wadhwa, Anil P Bidkar, Chandrashekhar Dasari, Changhua Mu, Ramya Ambur Sankaranarayanan, Juan A Camara Serrano, Athira Raveendran, David P Bulkley, Rahul Aggarwal und 7 weitere

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202304618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Niranjan Meher und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA. Hauptthemen laut MEDLINE: Polyethylene Glycols, Prostatic Neoplasms, Glutamate Carboxypeptidase II, Tomography, Emission-Computed, Single-Photon. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, U. S. Department of Energy, Science, Mathematics, And Research For Transformation Scholarship Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumor uptake of large non‐targeted nanocarriers primarily occurs through passive extravasation, known as the enhanced permeability and retention (EPR) effect. Prior studies demonstrated improved tumor uptake and retention of 4‐arm 40 kDa star polyethylene glycol (StarPEG) polymers for cancer imaging by adding prostate‐specific membrane antigen (PSMA) targeting small molecule ligands. To test PSMA‐targeted delivery and therapeutic efficacy, StarPEG nanodrugs with/without three copies of PSMA‐targeting ligands, ACUPA, are designed and synthesized. For single‐photon emission computed tomography (SPECT) imaging and therapy, each nanocarrier is labeled with 177Lu using DOTA radiometal chelator. The radiolabeled nanodrugs, [177Lu]PEG‐(DOTA)1 and [177Lu]PEG‐(DOTA)1(ACUPA)3, are evaluated in vitro and in vivo using PSMA+ PC3‐Pip and/or PSMA– PC3‐Flu cell lines, subcutaneous xenografts and disseminated metastatic models. The nanocarriers are efficiently radiolabeled with 177Lu with molar activities 10.8–15.8 MBq/nmol. Besides excellent in vitro PSMA binding affinity (kD = 51.7 nM), the targeted nanocarrier, [177Lu]PEG‐(DOTA)1(ACUPA)3, demonstrated excellent in vivo SPECT imaging contrast with 21.3% ID/g PC3‐Pip tumors uptake at 192 h. Single doses of 18.5 MBq [177Lu]PEG‐(DOTA)1(ACUPA)3 showed complete resolution of the PC3‐Pip xenografts observed up to 138 days. Along with PSMA‐targeted excellent imaging contrast, these results demonstrated high treatment efficacy of [177Lu]PEG‐(DOTA)1(ACUPA)3 for prostate cancer, with potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsProstatic NeoplasmsGlutamate Carboxypeptidase IITomography, Emission-Computed, Single-PhotonMaleAnimalsHumansMiceCell Line, TumorAntigens, SurfaceNanoparticlesLutetiumDrug CarriersRadioisotopesTissue DistributionMice, NudeHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

enhanced permeability and retentionpolymer nanocarriersprostate cancerprostate‐specific membrane antigen (PSMA)radioligand therapysingle photon excited computed tomography (SPECT) imaging

Substanzen

Polyethylene GlycolsGlutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, SurfaceLutetiumDrug CarriersRadioisotopesLutetium-177Heterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.
  • National Institute of Pharmaceutical Education and Research, Raebareli, Lucknow, UP, 226002, India.
  • ProLynx Inc., San Francisco, CA, 94158, USA.
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, 94143-0981, USA.
  • Division of Vascular and Endovascular Surgery, University of California, San Francisco, CA, 94143-0957, USA.
  • Department of Pathology, University of California, San Francisco, CA, 94143, USA.

ORCID-Profile: Niranjan Meher, Robert R Flavell

Förderung

  • NCI NIH HHS
  • U. S. Department of Energy
  • Science, Mathematics, And Research For Transformation Scholarship Program
  • NIH HHS

Zitieren

APA

Meher, N., Ashley, G. W., Bobba, K. N., Wadhwa, A., Bidkar, A. P., Dasari, C., Mu, C., Sankaranarayanan, R. A., Serrano, J. A. C., Raveendran, A., Bulkley, D. P., Aggarwal, R., Greenland, N. Y., Oskowitz, A., Wilson, D. M., Seo, Y., Santi, D. V., VanBrocklin, H. F., & Flavell, R. R. (2024). Prostate‐Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202304618

Vancouver

Meher N, Ashley GW, Bobba KN, Wadhwa A, Bidkar AP, Dasari C, et al. Prostate‐Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202304618

BibTeX
@article{Meher2024,
  author = {Meher, Niranjan and Ashley, Gary W and Bobba, Kondapa Naidu and Wadhwa, Anju and Bidkar, Anil P and Dasari, Chandrashekhar and Mu, Changhua and Sankaranarayanan, Ramya Ambur and Serrano, Juan A Camara and Raveendran, Athira and Bulkley, David P and Aggarwal, Rahul and Greenland, Nancy Y and Oskowitz, Adam and Wilson, David M and Seo, Youngho and Santi, Daniel V and VanBrocklin, Henry F and Flavell, Robert R},
  title = {Prostate‐Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202304618}
}
Kostenlos starten →